Latest Investors Conference Call
Founded and headquartered in Brisbane, Australia with US and European operations, ImpediMed is a medical software technology company that non-invasively measures, monitors and manages fluid status and tissue composition using bioimpedence spectroscopy (BIS).
ImpediMed produces a family of FDA-cleared and CE-marked medical devices, including SOZO® for multiple indications, including heart failure, protein calorie malnutrition and lymphedema, sold in select markets globally. ImpediMed’s connected digital health platform and large, attractive and growing markets present an opportunity for continued strong growth through its SOZO SaaS subscription-based business.
ImpediMed Limited is listed on the Australian Stock Exchange (ASX). Trading in its securities is under the ticker code on ASX of “IPD” for ordinary shares.
To update shareholder contact information or submit transfer documents, please contact ImpediMed’s share register service provider:
Locked Bag A14
NSW 1235, Australia
Shares may be bought on market through any Australian stock broker, or through on-market trades, via a number of international brokerage houses. If you are a potential investor needing information on how to trade in shares through an international brokerage house, please contact:
ImpediMed maintains an active communications program with investors and the market. If you are interested in a presentation, please contact:
Investor Relations Contact:
Mike Bassett, ImpediMed
+61 4 0743 1432
Kyahn Williamson, WE Buchan
+61 3 9866 4722